Workflow
APA(APA) - 2025 Q3 - Quarterly Report
2025-11-06 21:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 1-40144 APA CORPORATION (Exact name of registrant as specified in its charter) Delaware 86-1430562 (State o ...
PROCORE(PCOR) - 2025 Q3 - Quarterly Report
2025-11-06 21:05
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ ...
Onto Innovation(ONTO) - 2025 Q3 - Quarterly Results
2025-11-06 21:05
EXHIBIT 99.1 Onto Innovation Reports 2025 Third Quarter Results Wilmington, Mass., November 6, 2025 – Onto Innovation Inc. (NYSE: ONTO) ("Onto Innovation," "Onto," or the "Company") today announced financial results for the third quarter of 2025. Third Quarter Business and Financial Highlights: "The qualification of the 3Di technology for 3D bump metrology by two customers supporting HBM and another customer supporting 2.5D logic applications for AI is another great step forward by the Onto Innovation team ...
Ventyx Biosciences(VTYX) - 2025 Q3 - Quarterly Results
2025-11-06 21:05
Exhibit 99.1 Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress SAN DIEGO, CA, November 6, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported third quarter financial results and highlighted recent pipeline and business progress. "I am prou ...
Wynn Resorts(WYNN) - 2025 Q3 - Quarterly Results
2025-11-06 21:05
Exhibit 99.1 Wynn Resorts, Limited Reports Third Quarter 2025 Results LAS VEGAS, November 6, 2025 — Wynn Resorts, Limited (NASDAQ: WYNN) ("Wynn Resorts" or the "Company") today reported financial results for the third quarter ended September 30, 2025. Operating revenues were $1.83 billion for the third quarter of 2025, an increase of $140.4 million from $1.69 billion for the third quarter of 2024. Net income attributable to Wynn Resorts, Limited was $88.3 million for the third quarter of 2025, compared to n ...
eXp(EXPI) - 2025 Q3 - Quarterly Report
2025-11-06 21:05
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ______________________ Commission File Number: 001-38493 EXP WORLD HOLDINGS, INC. (Exact name of registrant as specified ...
Eventbrite(EB) - 2025 Q3 - Quarterly Report
2025-11-06 21:04
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-Q ____________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition perio ...
Midland States Bancorp(MSBI) - 2025 Q3 - Quarterly Report
2025-11-06 21:04
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission File Number 001-35272 1201 Network Centre Drive 62401 Effingham, IL (Zip Code) (Address of principal executive offices) (217) ...
MIDLAND STS(MSBIP) - 2025 Q3 - Quarterly Report
2025-11-06 21:04
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission File Number 001-35272 MIDLAND STATES BANCORP, INC. (Exact name of registrant as specified in its charter) (State of other jur ...
PAR(PAR) - 2025 Q3 - Quarterly Results
2025-11-06 21:04
FOR RELEASE: CONTACT: New Hartford, NY, November 6, 2025 Christopher R. Byrnes (315) 743-8376 chris_byrnes@partech.com, www.partech.com Exhibit 99.1 Year-to-Date 2025 Financial Highlights (2) | (in millions, except % and per share | GAAP | | | Non-GAAP | | (1) | | --- | --- | --- | --- | --- | --- | --- | | amounts) | Q3 2025 | Q3 2024 | vs. Q3 2024 | Q3 2025 | Q3 2024 | vs. Q3 2024 | | Revenue | $335.4 | $245.0 | better 36.9% | | | | | Net Loss from Continuing Operations/Adjusted EBITDA | $(63.8) | $(64.6) ...